Urogen Pharma Ltd.
A biotech whose gel turns liquid to jelly at body heat, letting cancer drugs linger in the urinary tract for hours instead of minutes. Its FDA-approved treatments Jelmyto and Zusduri offer non-surgical options for rare bladder and kidney-tube cancers. Born in 2004 as Theracoat, it renamed itself UroGen in 2015 and won its first approval in 2020.
Granted 10.0K · Sold 85.9K
Granted 2.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Schoenberg MarkChief Medical Officer · 5 transactions | -60.7% | 59.1K | 10.0K | — | 85.9K |
| Robinson James A. Jr.Director · 1 transaction | +200% | 6.0K | 2.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -85.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.